NCT00877500View on ClinicalTrials.gov

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

March 30, 2009

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Bilateral Breast CarcinomaHER2/Neu NegativeInvasive Breast Carcinoma

Interventions

OTHER

Best Practice

Receive standard of care

DRUG

Ixabepilone

Given IV

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

60453-2699

Advocate Christ Medical Center, Oak Lawn

77026-1967

Lyndon Baines Johnson General Hospital, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00877500 - Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | Biotech Hunter | Biotech Hunter